Metronomic chemotherapy using oral cyclophosphamide and bevacizumab for recurrent cervical cancer: A multi-institutional retrospective study

Isono-Taniguchi, Roze; Goto, Mayako; Takimoto, Yukinobu; Ueda, Tomoko; Wakimoto, Yu; Inoue, Kayo; Hori, Kensuke; Ito, Kimihiko; Taniguchi, Hiroshi

doi:10.1016/j.gore.2022.101013

Cited by 2 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A multi-institutional retrospective study on oral cyclophosphamide and bevacizumab included one case of large-cell NEC, and the PFS and OS of the patient was 2.2 and 13.6 months, respectively. 20 Two case reports on the treatment of cervical carcinoma have been published. The first was a case of small cell carcinoma, for which TC and bevacizumab therapy without bevacizumab single maintenance therapy was administered, and the status of no recurrence was maintained at 24 months after TC and bevacizumab therapy.…”

Section: Discussionmentioning

confidence: 99%

“…In that study, the PFS of the patient with small‐cell carcinoma was 5.9 months, and the status of no recurrence was maintained. A multi‐institutional retrospective study on oral cyclophosphamide and bevacizumab included one case of large‐cell NEC, and the PFS and OS of the patient was 2.2 and 13.6 months, respectively 20 . Two case reports on the treatment of cervical carcinoma have been published.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Paclitaxel‐carboplatin plus bevacizumab therapy for advanced neuroendocrine carcinoma of the uterine cervix: A retrospective case series

Kotaka,

Kondo,

Kawai

et al. 2023

J of Obstet and Gynaecol

View full text Add to dashboard Cite

AimThere is no conclusive data on the prognosis of patients who receive paclitaxel‐carboplatin (TC) plus bevacizumab therapy for advanced neuroendocrine carcinoma (NEC) of the uterine cervix, a rare histological subtype of cervical cancer. Thus, the aim of this study was to determine the efficacy of TC chemotherapy plus bevacizumab and bevacizumab single maintenance therapy for advanced NEC of the cervix.MethodsThis was a retrospective review of patients who received TC plus bevacizumab therapy for metastatic, recurrent, or persistent NEC of the cervix at seven institutions between 2015 and 2020. Relevant data were extracted from the patients' medical records and analyzed.ResultsSeven patients, including six with small‐cell NEC and one with large‐cell NEC, were included for analysis. Three patients received bevacizumab single maintenance therapy following TC plus bevacizumab therapy, whereas four patients did not receive bevacizumab single maintenance therapy. The median overall survival and progression‐free survival of the patients who received bevacizumab single maintenance therapy were longer than those of the patients who did not receive the therapy (34 months vs. 10.5 months and 19 months vs. 5 months, respectively). However, the patients who received bevacizumab single maintenance therapy had received cisplatin‐based chemotherapy previously.ConclusionsOn the premise that cisplatin‐based chemotherapy is administered as the first‐line treatment for advanced NEC of the cervix, bevacizumab single maintenance therapy following TC plus bevacizumab may be considered the second‐ or third‐line treatment. However, the risk of adverse events, such as intestinal perforation, should be discussed with patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%